Medication info
Trudiese MS Sustained Release Tablets 5/50/1000 mg (Dapagliflozin, Sitagliptin, Metformin)

Trudiese MS Sustained Release Tablets 5/50/1000 mg (Dapagliflozin, Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletDapagliflozin Propanediol Hydrate›6.15mg / 1 tabletSitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Boryung Co., Ltd.
Appearance
Light yellow, double convex, oval-shaped sustained-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500712 · Approved 2025.03.27 · Insurance code 641908650

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is 10 mg of dapagliflozin and 100 mg of sitagliptin. The dose of extended-release metformin hydrochloride is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal, preferably in the evening. If the dose of metformin hydrochloride needs to be adjusted, adjust it gradually. Patients taking this medicine as 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 5/50/1000 mg extended-release tablets should take 2 tablets together once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine should be 10 mg dapagliflozin, 100 mg sitagliptin, and the current dose of metformin hydrochloride or a therapeutically equivalent dose. For patients switching from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be the same as the previous doses of each component. Patients with renal impairment: As the efficacy and safety of this medicine depend on renal function and dosage adjustment according to renal function is required, it is recommended that renal function be assessed before treatment and periodically thereafter. No dose adjustment is necessary for patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other symptoms that may increase the risk of lactic acidosis. Since the starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If the estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months.

Ingredients

Manufacturer
Boryung Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication effectively helps control blood glucose levels in patients with type 2 diabetes when used in conjunction with dapagliflozin, sitagliptin, and metformin. It aids in improving blood glucose levels in combination with dietary management and exercise therapy. It supports patients in achieving more stable blood glucose control and is therefore actively used in the treatment of type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the recommended dose of this medicine is 10 mg of dapagliflozin and 100 mg of sitagliptin. The dose of extended-release metformin hydrochloride is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal, preferably in the evening. If the dose of metformin hydrochloride needs to be adjusted, adjust it gradually. Patients taking this medicine as 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 5/50/1000 mg extended-release tablets should take 2 tablets together once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine should be 10 mg dapagliflozin, 100 mg sitagliptin, and the current dose of metformin hydrochloride or a therapeutically equivalent dose. For patients switching from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be the same as the previous doses of each component. Patients with renal impairment: As the efficacy and safety of this medicine depend on renal function and dosage adjustment according to renal function is required, it is recommended that renal function be assessed before treatment and periodically thereafter. No dose adjustment is necessary for patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other symptoms that may increase the risk of lactic acidosis. Since the starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If the estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months.

Precautions

This medication contains three ingredients: sitagliptin, dapagliflozin, and metformin, and precautions should be taken regarding each ingredient. Firstly, sitagliptin can occasionally cause severe allergic reactions. If severe rash, swelling, or difficulty breathing occurs, stop taking the medication immediately and consult a doctor. Additionally, pancreatitis, which is inflammation of the pancreas, may occur, so if symptoms such as abdominal pain, vomiting, or fever arise after taking the medication, promptly inform medical personnel. Secondly, dapagliflozin can cause dehydration and low blood pressure, particularly in patients with impaired renal function, the elderly, or those on diuretics. This medication may increase the risk of genital and urinary tract infections; thus, if any infection symptoms occur, immediate treatment should be sought. Also, a rare side effect of severe perineal necrosis has been reported; if pain, swelling, or redness occurs around the genitals, seek immediate medical attention. Thirdly, metformin can rarely cause a serious metabolic disturbance known as lactic acidosis, which presents with symptoms such as vomiting, abdominal pain, shortness of breath, and lethargy. Patients with decreased renal function or poor liver function may be at risk when taking this medication, so regular kidney and liver function tests should be conducted before and during use. This medication should not be taken in special situations such as having certain diseases, being pregnant, experiencing acute heart failure, dehydration, severe infections, or being scheduled for surgery. Any changes in condition during use should be consulted with a doctor immediately. Lastly, symptoms of hypoglycemia may arise, so it is crucial to maintain a regular meal schedule and be mindful of the risk of hypoglycemia when exercising or combining with other drugs. While taking this medication, it is important to regularly monitor blood glucose and renal function and to quickly inform medical personnel of any unusual symptoms.

Side effects

  • Hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative dermatitis
  • acute pancreatitis
  • hemorrhagic pancreatitis
  • necrotizing pancreatitis
  • lactic acidosis
  • hypoglycemia
Show 109 more
  • vulvitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • perineal necrosis
  • decreased fluid volume
  • thirst
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • interstitial nephritis
  • increased hematocrit
  • elevated serum creatinine
  • dyslipidemia
  • rash
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • gastroesophageal reflux disease
  • epigastric pain
  • diverticulosis
  • intestinal perforation
  • chronic pancreatitis
  • hyperglycemia
  • paresthesia
  • cerebral infarction
  • nerve compression
  • sinusitis
  • diverticulitis
  • pelvic inflammatory disease
  • pneumonia
  • pulmonary tuberculosis
  • asthenia
  • pain
  • ligament sprain
  • road traffic accident
  • drug overdose
  • ankle fracture
  • hand fracture
  • pelvic fracture
  • meniscal injury
  • thoracic spine fracture
  • tibial fracture
  • keratitis
  • chronic obstructive pulmonary disease
  • hemoptysis
  • cerebral hemorrhage
  • peripheral artery occlusion
  • angina pectoris
  • myocardial infarction
  • bile duct stones
  • cholangitis
  • alcoholic liver cirrhosis
  • depression
  • suicide attempt
  • gastric adenocarcinoma
  • anaphylactic reaction
  • acute pyelonephritis
  • chest pain
  • dyspepsia
  • nausea
  • diarrhea
  • vomiting
  • urinary retention
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • decreased appetite
  • next syndrome
  • headache
  • nasopharyngitis
  • asthenia
  • hunger
  • vaginal discharge
  • menstrual irregularities
  • itching
  • urticaria
  • arthralgia
  • musculoskeletal pain
  • limb pain
  • muscle weakness
  • myalgia
  • osteoarthritis
  • ligament sprain
  • diabetic retinopathy
  • cough
  • shortness of breath
  • orthostatic hypotension
  • palpitations
  • insomnia
  • fatty liver
  • gallbladder polyp
  • tinnitus
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
  • itching
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from exposure to air and moisture. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Light yellow, double convex, oval-shaped sustained-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.